Jyong Biotech Ltd. (MENS) Key Metrics
MENS key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMENS returns How much profit the business earns on the capital it uses.
MENS per-share figures Results divided by the shares outstanding at year-end.
MENS financial health Debt, liquidity and how easily interest is covered.
MENS efficiency & capital use Working capital cycle and where the cash goes.
MENS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MENS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MENS price vs earnings per share
MENS key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $288.4M | — | — | — | — | — |
| Enterprise value | $305.8M | — | — | — | — | — |
| Earnings yield | −1.6% | — | — | — | — | — |
| Free cash flow yield | −1.1% | — | — | — | — | — |
| Share price at fiscal year-end | $3.95 | — | — | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$0.06 | −$0.04 | −$0.06 | −$0.09 | −$0.06 | −$0.03 |
| Operating cash flow per share | −$0.04 | −$0.05 | −$0.03 | −$0.04 | −$0.03 | −$0.02 |
| Free cash flow per share | −$0.04 | −$0.05 | −$0.03 | −$0.04 | −$0.03 | −$0.02 |
| Cash per share | $0.02 | $0.00 | $0.00 | $0.01 | $0.03 | $0.06 |
| Book value per share | −$0.34 | −$0.48 | −$0.45 | −$0.39 | −$0.31 | −$0.27 |
| Tangible book value per share | −$0.34 | −$0.48 | −$0.45 | −$0.39 | −$0.31 | −$0.27 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.25 | $0.24 | $0.22 | $0.19 | $0.16 | $0.19 |
| Shares outstanding | 73.0M | 76.0M | 76.0M | 76.0M | 76.0M | 71.6M |
| Change in shares outstanding | −4.0% | 0.0% | 0.0% | 0.0% | +6.2% | — |
| Returns & profitability | ||||||
| Return on assets (ROA) | −34.4% | −41.3% | −51.8% | −72.9% | −37.7% | −14.9% |
| Return on tangible assets | −22.5% | −47.4% | −53.3% | −75.8% | −44.5% | −14.9% |
| Financial health | ||||||
| Total debt | $18.5M | $18.1M | $16.7M | $14.3M | $11.8M | $13.6M |
| Cash & short-term investments | $1.2M | $98,000 | $177,000 | $812,000 | $2.4M | $4.2M |
| Net debt | $17.4M | $18.0M | $16.5M | $13.4M | $9.4M | $9.4M |
| Debt / assets | 0.89 | 2.85 | 2.02 | 1.63 | 1.25 | 1.06 |
| Current ratio | 0.45 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Quick ratio | 0.45 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Interest coverage | -1.0 | -2.0 | -3.7 | -3.7 | -2.9 | -2.9 |
| Working capital | −$19.3M | −$11.9M | −$12.4M | −$10.4M | −$3.6M | $443,000 |
| Invested capital | −$7.5M | −$18.5M | −$17.6M | −$16.2M | −$13.9M | −$9.8M |
| Tangible asset value | −$24.9M | −$36.5M | −$34.1M | −$29.6M | −$23.3M | −$19.2M |
| Net current asset value | −$30.1M | −$42.7M | −$40.5M | −$35.9M | −$30.1M | −$25.8M |
| Graham net-net per share | −$0.47 | −$0.56 | −$0.55 | −$0.49 | −$0.40 | −$0.39 |
| Capital allocation | ||||||
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 2.00 | 1.12 | 0.80 |
| Efficiency | ||||||
| Days payables outstanding | 9.1 | 7.6 | 8.6 | 74.8 | 107.1 | — |
| Receivables turnover | 0.00 | — | — | — | — | — |
| Payables turnover | 40.00 | 48.00 | 42.33 | 4.88 | 3.41 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $13.5M | — | — | — | — | — |
| Average payables | $2,500 | $2,500 | $3,000 | $25,000 | $35,500 | $25,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MENS's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MENS valuation and financial ratios
It ended the year with $18.5 million of debt and $1.2 million in cash and short-term investments, net debt of $17.4 million.
See the MENS income statement, the MENS chart for price history, or the MENS stock overview for the latest quote and news.
MENS key metrics FAQ
How much debt does Jyong Biotech have?
Jyong Biotech had total debt of $18.5 million at the end of fiscal 2025.
What is Jyong Biotech's free cash flow yield?
Jyong Biotech generated -$3.0 million of free cash flow in fiscal 2025, a free cash flow yield of −1.1% on its market value at year-end ($288.4 million).
What is Jyong Biotech's current ratio?
Jyong Biotech's current ratio was 0.45 at the end of fiscal 2025: current assets were 0.45 times current liabilities.